Abstract 2958: BSI-508, a novel bispecific fusion molecule targeting PD1 and CD47 for cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2958
Abstract: Introduction: While anti-PD1/PDL1 mAbs have shown success in the market only a small fraction of patients actually benefit from the therapies. Novel approaches to improve outcomes for patients who are resistant or refractory to current… read more here.
Keywords: bispecific fusion; fusion; anti pd1; molecule ... See more keywords